Mandate

Vinge advises Dreams in connection with the divestment of Dreams Technology

February 27, 2023 M&A

Vinge advises Dreams AB in connection with the divestment of the leading engagement banking platform Dreams Technology to Doconomy which expands suite of climate action tools and empowers banks to better engage their customers.

Dreams Technology is a Stockholm-based financial wellbeing fintech with a leading engagement banking platform based on cognitive and behavioral science, helping the financial industry create strong customer relationships and attract the next generation while addressing financial wellbeing and sustainability. Doconomy is the leading climate technology startup helping banks, brands, and consumers to better understand and reduce their environmental impact. Through the transaction, Doconomy becomes the first provider to offer a holistic solution that drives meaningful climate and social impact for the financial services industry.

Vinge’s team consisted of Jonas Johansson, Eléonore Friberg and Stojan Arnerstål.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026